Welcome to our dedicated page for Pharvaris N.V. news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris N.V. stock.
Pharvaris N.V. (PHVS) news centers on its progress as a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema. Company updates frequently highlight clinical milestones for its lead candidate deucrictibant, including pivotal Phase 3 programs in hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
Investors following PHVS news can expect detailed announcements on clinical trial results and timelines. Recent releases describe RAPIDe-3, a pivotal global Phase 3 study of deucrictibant immediate-release capsule for on-demand treatment of HAE attacks, which met its primary endpoint and all secondary efficacy endpoints with statistical significance and was reported as well tolerated. Other updates cover CHAPTER-3 and CHAPTER-4, Phase 3 studies of the extended-release tablet for long-term prophylaxis of HAE attacks, and CHAPTER-1 Phase 2 data showing sustained reductions in attack rates over long-term treatment.
Pharvaris news also includes information on the CREAATE Phase 3 study in AAE-C1INH, presentations of deucrictibant data at major medical congresses, and summaries of biomarker work such as the kinin assay being clinically validated to characterize bradykinin-mediated angioedema. Financial and corporate updates, including quarterly results, cash runway commentary, and details of public offerings of ordinary shares and pre-funded warrants, are furnished through press releases and Form 6-K filings.
For readers tracking PHVS, this news stream provides insight into the advancement of deucrictibant’s prophylactic and on-demand indications, regulatory filing plans such as the preparation of marketing authorization applications, and the company’s broader efforts in bradykinin-mediated diseases.
Pharvaris (Nasdaq: PHVS) presented data at CIIC Spring 2026 showing that combined use of a 40 mg deucrictibant XR prophylactic tablet with one or two 20 mg IR capsules for breakthrough attacks is supported by calculated safety margins. A post-hoc CHAPTER-1 analysis showed comparable mean durations for icatibant-treated attacks across placebo and deucrictibant arms, offering initial evidence for the mechanism-on-mechanism approach. Pharvaris highlighted safety and early efficacy signals and said it will further explore combined prophylactic and on-demand deucrictibant use.
Pharvaris (Nasdaq: PHVS) reported Q4 and full-year 2025 results and provided a business update on deucrictibant clinical programs. Key milestones: CHAPTER-3 enrollment complete with topline data expected in 3Q2026, RAPIDe-3 pivotal success supports an on-track NDA submission in 1H2026, and cash of €292 million at year-end.
Company continues enrollment in CREAATE and long-term CHAPTER-4 extension while highlighting RAPIDe-3 median onset and resolution times versus placebo.
Pharvaris (Nasdaq: PHVS) announced publication of two Phase 2 trials in The Lancet Haematology showing deucrictibant, an oral bradykinin B2 receptor antagonist, had statistically significant efficacy and was well tolerated for both prophylaxis (CHAPTER-1) and on-demand treatment (RAPIDe-1) of hereditary angioedema (HAE) attacks.
The company said CHAPTER-1 showed reduced attack occurrence and improved quality of life, while RAPIDe-1 showed reduced attack severity and faster symptom relief; Phase 3 topline from CHAPTER-3 is expected in Q3 2026.
Pharvaris (Nasdaq: PHVS) published a peer-reviewed study validating patient-reported outcome (PRO) instruments for on-demand hereditary angioedema (HAE) treatment endpoints.
The non-interventional, mixed-methods study found PGI and AMRA tools reliable and sensitive, identified End of Progression™ as earliest meaningful endpoint, and aligned PGI-C "a little better" with AMRA-3 ≥20%, informing Phase 3 RAPIDe-3 endpoint hierarchy.
Pharvaris (Nasdaq: PHVS) presented Phase 3 RAPIDe-3 and Phase 2 CHAPTER-1 data at AAAAI 2026 supporting deucrictibant for on‑demand and prophylactic treatment of bradykinin‑mediated angioedema.
RAPIDe-3 met the primary and all 11 secondary endpoints: median onset of symptom relief 1.28 hours and complete resolution 11.95 hours versus much longer placebo times. CHAPTER-1 OLE showed mean attack rate fell from 2.18 to 0.12 attacks/month and roughly half of participants were attack free; no treatment‑related serious adverse events reported.
Pharvaris (Nasdaq: PHVS) will present six abstracts, including three Featured Posters, at the AAAAI 2026 Annual Meeting in Philadelphia from February 27–March 2, 2026. Key topics include pivotal Phase 3 RAPIDe-3 on-demand data, final CHAPTER-1 open-label results, and extended-release pharmacokinetics for CHAPTER-3.
Topline CHAPTER-3 results are anticipated in Q3 2026. Posters and slides will be posted on the company's investor site at the start of each presentation.
Pharvaris (NASDAQ: PHVS) outlined 2026 priorities focused on late‑stage development and regulatory filings for oral deucrictibant for bradykinin‑mediated angioedema. Key milestones: topline CHAPTER‑3 prophylaxis data expected 3Q2026; NDA preparation for on‑demand HAE treatment targeted for filing in 1H2026 based on RAPIDe‑3 and RAPIDe‑2; RAPIDe‑3 met its primary and all secondary endpoints with median onset of symptom relief of 1.28 hours (p<0.0001). CREAATE pivotal study in AAE‑C1INH is enrolling; CHAPTER‑4 long‑term extension is ongoing; CHAPTER‑1 open‑label data showed mean on‑treatment monthly attack rate of 0.12. Corporate runway is estimated into 1H2027, and Pharvaris was added to the Nasdaq Biotechnology Index in Dec 2025.
Pharvaris (NASDAQ: PHVS) reported positive topline results from the RAPIDe-3 pivotal Phase 3 study of oral deucrictibant IR 20 mg for on-demand treatment of hereditary angioedema (HAE) attacks.
The primary endpoint was met: median time to onset of symptom relief was 1.28 hours vs >12 hours for placebo (p<0.0001). All 11 secondary endpoints were significant, including End of Progression™ 17.47 minutes/b vs 228.67 minutes and median time to complete symptom resolution Deucrictibant was well tolerated with no treatment-related serious adverse events; NDA filings are planned starting H1 2026.
Pharvaris (Nasdaq: PHVS) reported Q3 2025 results and a business update highlighting pivotal Phase 3 programs for deucrictibant. RAPIDe-3 (on-demand HAE, 20 mg immediate-release) reached ~120 participants and topline data are expected in 4Q2025. CHAPTER-3 (prophylaxis, 40 mg extended-release) enrollment is progressing with topline data anticipated in 2H2026. Pharvaris initiated CREAATE (AAE-C1INH pivotal study) and reported Phase 2 CHAPTER-1 OLE on-treatment attack rate of 0.12. Corporate financing included a public offering with proceeds of approximately $201 million. Cash and cash equivalents were €329 million as of September 30, 2025, providing runway into H1 2027. Q3 operating metrics: R&D €29.8M, G&A €9.8M, net loss €37.1M (loss per share €0.60).
Pharvaris (Nasdaq: PHVS) presented clinical and biomarker data at ACAAI 2025 highlighting deucrictibant's long-term safety, sustained efficacy, and a validated kinin assay.
Key data: open-label CHAPTER-1 extension showed treatment for up to ~34 months with mean attacks reduced from 2.18 to 0.12 attacks/month and an average 92.4% attack reduction; RAPIDe-2 Part A reported a median time-to-onset of symptom relief of 1.1 hours and median time-to-resolution of 10.6 hours with 89.2% of attacks resolved at 24 hours after a single dose.
The company also reported a clinically validated plasma kinin biomarker assay and reiterated expected pivotal readouts: CHAPTER-3 in H2 2026 and RAPIDe-3 in Q4 2025.